PD-L1 Expression and Histopathological Features in EGFR-Mutated Non-Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR-Tyrosine Kinase Inhibitors Resistance.

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) responds well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), yet optimal therapy after resistance remains uncertain. Although immune checkpoint inhibitors (ICIs) show limited overall efficacy, heterogeneity in response by programmed cell death ligand 1 (PD-L1) expression exists. METHODS: We retrospectively evaluated...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged, 80 and over
• Share to B7-H1 Antigen